Advarra has introduced a new platform called SiteIQ to expedite clinical trial start-up by facilitating protocol planning and site selection processes.

The platform leverages Advarra’s data resources and expertise to offer insights regarding clinical research site experience, capacity, quality and performance among others. It will also help in identifying the right participants for the trial.

The launch of SiteIQ is expected to help trial sponsors and contract research organisations (CRO) in making informed decisions on site selection and feasibility processes.

It also procures third-party data to offer curated recommendations to meet specific study requirements.

Swiss multinational biopharmaceutical company Ferring Pharmaceuticals is an early adopter of SiteIQ.

Ferring Pharmaceuticals Clinical Business Operations director Lindsey Mathew said: “In my experience as a big pharma sponsor, a mid-size sponsor, and a large CRO, having the ability to choose from a properly vetted selection of sites is critical.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The lack of transparency in site quality, mixed with personal relationships with investigators, can create bias in the selection process that every sponsor wants to avoid.

“Advarra’s service has proven time and time again to offer up a range of investigators that even adds to our efforts to ensure a diverse patient population more representative of the patients we hope to serve in the future.”

Advarra chief technology officer Jeff Sidell said: “SiteIQ demonstrates our commitment to bridging the research ecosystem and connecting sponsors, sites, and patients through improved workflows and advanced technology solutions.

“With this holistic approach, we are addressing a key industry challenge through a data-driven solution.”

Based in the US, Advarra focuses on providing regulatory review solutions. Earlier this year, the company launched the Insights Accrual Prediction Platform.